Your basket is currently empty!
Cabo + nivo & ipi delays kidney cancer progression
Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...
News Archive
Nivolumab
Kidney Cancer UK represents patients at NICE nivo+ipi appraisal
On 3rd February 2022, NICE approve the use of nivolumab with ipilimumab as a first line treatment for kidney ...
Nivolumab+Sitravatinib Combo Impresses in RCC
Combining a broad-spectrum tyrosine kinase inhibitor (TKI) with an immune checkpoint inhibitor resulted in a high ...
SMC Recommend nivolumab + ipilimumab for 1st line Rcc
By: Maureen Johnson - RGN, BSc (hons) Physiology
Kidney Cancer Scotland and Northern Ireland Health ...
NICE recommend nivolumab + ipilimumab combo through CDF
Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has ...
European Commission approves nivolumab ipilimumab combo
The European Commission has approved nivolumab in combination with low-dose ipilimumab for first-line treatment of ...
CHMP adopts a positive opinion of nivolumab + ipilimumab as 1st line treatment
Press release: Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo® (nivolumab) ...
Nivolumab Dosing Schedules Approved for Europe
A 4-week dosing schedule for nivolumab (Opdivo) has been approved by the European Commission for the treatment of ...
Nivolumab approved for monthly use in USA
US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option ...
Nivolumab Improves 3-year Overall Survival in Previously Treated Renal Cell Carcinoma
Updated results from a phase 3 study demonstrated that patients with advanced renal cell carcinoma (RCC) treated with nivolumab had significantly superior rates of 3-year overall survival (OS) compared with everolimus,
kidney cancer drug test stopped after early success
(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall ...
SMC approve of nivolumab and cabozantinib
Statement from Kidney Cancer Scotland on the news of the SMC’s approval of nivolumab and cabozantinib for late ...
